Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO) IRCCS, Milan, Italy; Molecular Medicine Program, University of Pavia, Pavia, Italy.
Eur J Cancer. 2021 Sep;154:246-252. doi: 10.1016/j.ejca.2021.06.029. Epub 2021 Jun 30.
Specific data regarding coronavirus disease 2019 (COVID-19) in patients with neuroendocrine neoplasms (NENs) are lacking. The aim of this study is to describe the characteristics of patients with NENs who tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive.
This is a worldwide study collecting cases of patients with NENs along with a positive nasopharyngeal swab reverse transcriptase-polymerase chain reaction (RT-PCR) test for SARS-CoV-2 between June 1, 2020, and March 31, 2021. Centres treating patients with NENs were directly contacted by the principal investigator. Patients with NENs of any primary site, grade and stage were included, excluding small-cell lung carcinoma and mixed adenoneuroendocrine carcinoma.
Among 81 centres directly contacted, 88.8% responded and 48.6% of them declined due to lack of cases or interest. On March 31, 2021, eight recruiting centres enrolled 89 patients. The median age was 64 years at the time of COVID-19 diagnosis. Most patients had metastatic, non-functioning, low-/intermediate-grade gastroenteropancreatic NENs on treatment with somatostatin analogues and radioligand therapy. Most of them had comorbidities. Only 8% of patients had high-grade NENs and 12% were receiving chemotherapy. Most patients had symptoms or signs of COVID-19, mainly fever and cough. Only 3 patients underwent sub-intensive treatment, whereas most of them received medical therapies, mostly antibiotics. In two third of cases, no changes occurred for the anti-NEN therapy. More than 80% of patients completely recovered without sequelae, whereas 7.8% patients died due to COVID-19.
Patients included in this study reflect the typical NEN population regardless of SARS-CoV-2. In most cases, they overcome COVID-19 without need of intensive care, short-term sequelae and discontinuation of systemic oncological therapy.
关于伴有神经内分泌肿瘤（NENs）的新型冠状病毒病 2019（COVID-19）患者的具体数据尚缺乏。本研究旨在描述新型冠状病毒 2（SARS-CoV-2）检测阳性的 NEN 患者的特征。
这是一项在 2020 年 6 月 1 日至 2021 年 3 月 31 日期间，收集伴有 SARS-CoV-2 鼻咽拭子逆转录-聚合酶链反应（RT-PCR）阳性的 NEN 患者病例的全球性研究。主要研究者直接联系了治疗 NEN 患者的中心。纳入任何原发部位、分级和分期的 NEN 患者，排除小细胞肺癌和混合性腺神经内分泌癌。
在直接联系的 81 个中心中，88.8%的中心做出回应，48.6%的中心因缺乏病例或兴趣而拒绝。截至 2021 年 3 月 31 日，8 个招募中心共纳入 89 例患者。COVID-19 诊断时的中位年龄为 64 岁。大多数患者患有转移性、无功能性、低/中分级胃肠胰腺 NENs，正在接受生长抑素类似物和放射性配体治疗。大多数患者存在合并症。仅有 8%的患者为高级别 NENs，12%的患者正在接受化疗。大多数患者有 COVID-19 的症状或体征，主要为发热和咳嗽。仅有 3 例患者接受了亚强化治疗，而大多数患者接受了医疗治疗，主要是抗生素。在三分之二的病例中，抗 NEN 治疗未发生变化。超过 80%的患者完全康复，无后遗症，而 7.8%的患者因 COVID-19 死亡。
纳入本研究的患者反映了典型的 NEN 人群，无论 SARS-CoV-2 状态如何。在大多数情况下，他们无需重症监护、短期后遗症和停止全身肿瘤治疗即可战胜 COVID-19。
